Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724841 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
A Phase 1 study, sponsored by Gemin X.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00724841: Clinical Trial Phase 1 study, sponsored by Gemin X.
NCT00724841 is a Phase 1 study that was terminated before completion, run by Gemin X. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00724841, a Phase 1 study, was terminated before completion, sponsored by Gemin X.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.
Interventions
- DRUG Temozolomide
- DRUG Obatoclax Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Why NCT00724841 stopped before completion
NCT00724841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT00724841 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00724841 about?
NCT00724841 is a clinical study titled "A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma". Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.
What is the current status of trial NCT00724841?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2008-06. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00724841?
The interventions under investigation include: Temozolomide (DRUG), Obatoclax Mesylate (DRUG).
Who is sponsoring clinical trial NCT00724841?
This trial is sponsored by Gemin X, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00724841's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia